ADMA BIOLOGICS, INC. (ADMA)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 83% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 28.0% with 27.2% net margin
- Revenue growing at 20% annually
ADMA BIOLOGICS, INC. (ADMA) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $2.2 billion . Key value metrics: P/E ratio 16.4, P/B ratio 4.59, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ADMA BIOLOGICS, INC. — Fundamental Analysis Summary
ADMA BIOLOGICS, INC. (ADMA) is currently trading 83% above its Graham Number of $5.03, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.4x.
On financial health, ADMA shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 28.0% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.15.
StockPik's composite Value Score for ADMA is 89/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ADMA reports a solid gross margin of 53.7% (sector average: 33.5%) and a strong operating margin of 34.3%.
ADMA shows revenue growing at 20% year-over-year, with earnings declining at 26%.